AlphAIAlphAI — Financial news for AI agents
finanznachrichten.deSEP 222 min read$LTRN

Lantern Pharma Inc.: Lantern Pharma Secures USPTO Notice of Allowance for LP-284 Treatment Patent in Aggressive B-Cell Lymphomas

Lantern Pharma (LTRN) received a USPTO Notice of Allowance for LP-284, extending patent protection to 2042 for treating mantle cell lymphoma and double-hit lymphoma. The patent covers LP-284 as a monotherapy and in combination with other anti-cancer agents. LP-284 is in a Phase 1 clinical trial and has three FDA Orphan Drug Designations.

Original reporting
finanznachrichten.de
Published Sep 22, 2026, 12:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 12:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$LTRN
Bullish
medium confidence
Mentioned
$LTRN
Relevance
6/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$LTRNBullishLow
01

Why it matters

The new method‑of‑use patent adds a layer of protection beyond the existing composition‑of‑matter estate, extending exclusivity to 2042 and may improve the company's long‑term valuation outlook.

02

Market read

The patent allowance is a material corporate development for LTRN, offering extended market exclusivity and potentially supporting future financing or partnership discussions.

03

What to watch

Potential challenges in regulatory approval and competition from other acylfulvene candidates could offset the IP benefit.

Relevance 6/10Novelty 7/10Timing: Sep 22 2026 (date of announcement)

Background

Lantern Pharma (NASDAQ:LTRN) is an AI‑driven precision oncology company developing LP‑284, an investigational acylfulvene for aggressive B‑cell lymphomas.

Company-level read

Ticker impact

$LTRNBullishMedium confidence
Context

Lantern Pharma received a USPTO Notice of Allowance extending LP-284 patent protection to 2042, a first‑report corporate development.

Expected impact

Modest upside as the extended patent horizon could improve long‑term cash‑flow expectations.

Evidence & confidence

Patent extensions are material for biotech valuations but the company remains early‑stage with limited near‑term revenue.

Market effects

Sector

Strengthens the IP position of AI‑driven oncology platforms, may raise confidence in similar biotech pipelines.

Regional

US biotech investors may view the filing as a positive signal for US‑listed precision‑oncology firms.

Global

Limited; primarily relevant to investors tracking early‑stage oncology drug developers.

Counterpoint

What could challenge this read

The extended patent may not translate into commercial value without successful trial data, keeping the stock speculative.

Key entities

  • company
    Lantern Pharma Inc.

    Developer of LP‑284, AI‑driven oncology platform.

  • regulator
    U.S. Patent and Trademark Office

    Issued the Notice of Allowance for the LP‑284 method‑of‑treatment patent.

Read at source← All news

Related articles

AUG 21
$LTRNMed

Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript

Lantern Pharma (LTRN) reported Q2 2026 earnings with $7.1M net loss, $7.4M cash, and reduced R&D expenses. LP-300 showed 8.9-month median PFS in L858R patients. The company is advancing LP-184 trials and plans to raise capital for Open Medicine AI, a new AI subsidiary. Management highlighted potential partnerships and cost efficiencies.

fool.com2 min
AUG 14
$LTRNMed

Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

Lantern Pharma Inc. (LTRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update Open Medicine AI Established as a Separate Company with Executed Commercial Licenses; Progression-Free Survival Benefit Deepens in EGFR Exon 21 L858R Lung Cancer with LP-300; EM

SEC EDGAR 8-K6 min
JUL 23
$LTRNMed

Lantern Pharma Receives U.S. Patent Allowance for LP

Lantern Pharma (NASDAQ: LTRN) said the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent covering patient selection and treatment for ovarian, primary liver, kidney and thyroid cancers using LP-184 (zirdafulven). The allowed claims relate to a three-gene biomarker signature (PTGR1, PTPN14, ASPH). Lantern cited a 45% disease control rate at or above the effective dose in Phase 1a and plans multiple Phase 1b/2 studies in 2026.

citybuzz.co3 min
OCT 3
$UNI-USDMed

Uniswap Eyes Institutional DeFi Expansion as Japan Gateway Meets Revenue Growth

Uniswap is collaborating with SMBC Nikko, Nethermind, Base, and Nyx Foundation to develop a Japan-focused DeFi Gateway, targeting mid-2027 completion. The project aims to create compliant liquidity pools using Uniswap v4 hooks. Uniswap reported $14.7 million in September revenue, with 53% from Robinhood Chain. UNI price is consolidating, with a potential breakout from a falling wedge pattern.

tronweekly.com2 min
OCT 3
$MRNAHighAI 8/10

Moderna (MRNA) Surges 37% in September Despite Healthcare Sector

Moderna (MRNA) surged 37.22% in September due to promising Phase 3 results for its personalized mRNA cancer vaccine, outperforming the broader healthcare sector. The company's P/S ratio is 33.44, significantly higher than its historical median of 8.41, reflecting high growth expectations. Moderna remains unprofitable, with a GF Score of 54/100, indicating mixed financial health. Insider activity shows significant selling, while guru ownership is mixed.

gurufocus.com2 min